profit from every $100 of sales.
$0$100
Bicara Therapeutics
$10.02-0.89% today
-35.6% in 1 year
1-year low $7.931-year high $30.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bicara Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$138 million of profit last year.
SalesProfit
Bicara Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bicara Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Bicara Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -38 | -40 | -82 | -156 | |
| -38 | -40 | -82 | -155 | |
| -38 | -52 | -68 | -138 | |
| -2.45 | -1.53 | -4.05 | -2.52 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 7 | 234 | 510 | 431 |
| Cash | 4 | 230 | 490 | 97 |
| Total debt | 0 | 1 | 1 | 2 |
| Total liabilities | 106 | 383 | 18 | 30 |
| -99 | -149 | 492 | 401 | |
| 15 | 34 | 17 | 55 | |
| – | – | -13.2% | -30.5% | |
| 38.3% | 34.9% | -13.8% | -34.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -32 | -46 | -75 | -107 | |
| 0 | 1 | 0 | 0 | |
| -32 | -46 | -75 | -107 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 2 | 7 | 15 |
Valuation
- –
- –
- –
- 2.2×
- –
- –
- –
- -16.1%
- -20.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -33.8%
- 36.8%
- -35.9%
- -28.4%
- -33.8%
- –
Growth
- –
- –
- −43.2%
- –
- +1.8%
Financial health
- 1.9×
- 0.00
- 0.3%
- –
- 13.85
- 13.85
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 946
Bottom 21%of 871
Bottom 6%of 986
What analysts expect
- Average price target
- $20.00
- Range
- $14.00 – $28.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.93 | -0.64 | −45.3% |
| Mar 26, 2026 | -0.68 | -0.72 | +5.6% |
| Nov 10, 2025 | -0.67 | -0.55 | −21.8% |
| Aug 12, 2025 | -0.50 | -0.54 | +7.4% |
| May 13, 2025 | -0.68 | -0.40 | −70.0% |
| Mar 27, 2025 | -0.39 | -0.31 | −25.8% |
| Nov 12, 2024 | -1.60 | -0.46 | −247.8% |
| Sep 13, 2024 | -0.27 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
34No pass
Benjamin Graham
52No pass
Philip Fisher
44No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
45No pass
Terry Smith
42No pass
Questions about Bicara Therapeutics
Is Bicara Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bicara Therapeutics AI analysis
What does Bicara Therapeutics do?
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. It is in Biotechnology.
Does Bicara Therapeutics pay a dividend?
No. Bicara Therapeutics does not pay a dividend at the moment.
Is Bicara Therapeutics stock halal?
Questionable. Bicara Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Bicara Therapeutics stock done over the past year?
Down 35.6% over the past twelve months, to $10.02. It traded between $7.93 and $30.40 and is 67.0% below its high.
Who are Bicara Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Bicara Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.